Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06199479 · ClinicalTrials.gov registry record · Phase 1
Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies
A Phase 1 study of Brain Malignancies and Pseudoprogression, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06199479 is a Phase 1 study of Brain Malignancies and Pseudoprogression that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06199479, a Phase 1 study of Brain Malignancies and Pseudoprogression, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if advanced imaging methods can tell apart true progression (the disease has actually gotten worse) from pseudoprogression (the disease appears to have gotten worse, but it actually has not).
Conditions Studied
Interventions
- PROCEDURE Biopsy
- PROCEDURE MRI Scan
- PROCEDURE CT Scan
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06199479
The ClinicalTrials.gov registry entry for NCT06199479 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Biopsy is the first listed.
NCT06199479 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06199479 about?
NCT06199479 is a clinical study titled "Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies". To learn if advanced imaging methods can tell apart true progression (the disease has actually gotten worse) from pseudoprogression (the disease appears to have gotten worse, but it actually has not).
What is the current status of trial NCT06199479?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-06-04. Estimated completion is 2027-10-31.
What conditions does trial NCT06199479 study?
This clinical trial studies the following conditions: Brain Malignancies, Pseudoprogression.
What interventions are being tested in trial NCT06199479?
The interventions under investigation include: Biopsy (PROCEDURE), MRI Scan (PROCEDURE), CT Scan (PROCEDURE).
Who is sponsoring clinical trial NCT06199479?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06199479 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.